Addex-Ammoniumklorid (Ammonium Chloride)
Intravenous electrolyte concentrate for the treatment of metabolic alkalosis
Quick Facts about Addex-Ammoniumklorid
Key Takeaways about Addex-Ammoniumklorid
- Hospital-only medication: Addex-Ammoniumklorid is a concentrated intravenous solution that must be diluted before administration and is given only by healthcare professionals in a clinical setting
- Used for metabolic alkalosis: The primary indication is correction of metabolic alkalosis (elevated blood pH above 7.45), which can result from prolonged vomiting, nasogastric suction, or diuretic therapy
- Contraindicated in severe liver disease: The drug must not be used in patients with severe hepatic impairment because the liver is required to metabolize ammonium to urea
- No reported side effects at recommended doses: When administered according to dosing guidelines, no adverse effects have been documented; however, overdose can cause metabolic acidosis
- Requires monitoring: Blood gas analysis and electrolyte monitoring are essential during treatment to guide dosing and prevent overcorrection
What Is Addex-Ammoniumklorid and What Is It Used For?
Addex-Ammoniumklorid is a concentrated electrolyte solution containing ammonium chloride (4 mmol/ml) that belongs to the group of acidifying electrolyte preparations. It is given as an intravenous infusion after dilution to correct metabolic alkalosis, a condition where the blood pH is abnormally high.
Metabolic alkalosis is a relatively common acid-base disturbance encountered in hospitalized patients, particularly in intensive care settings. It occurs when there is an excess of bicarbonate (HCO3−) in the blood, leading to a pH above 7.45. This condition can arise from various clinical scenarios and, if left untreated, can impair cardiac function, reduce oxygen delivery to tissues, and cause neurological symptoms such as confusion and muscle twitching.
Addex-Ammoniumklorid works through a well-understood biochemical mechanism. When ammonium chloride enters the bloodstream, the ammonium ions (NH4+) are transported to the liver, where they are converted to urea through the urea cycle. This metabolic conversion releases hydrogen ions (H+) and chloride ions (Cl−) into the systemic circulation. The hydrogen ions directly neutralize the excess bicarbonate, while the chloride ions help correct the frequently accompanying hypochloremia (low blood chloride levels).
The medication is manufactured by Fresenius Kabi, a global healthcare company specializing in intravenous therapies and clinical nutrition. It is supplied as a concentrated solution in glass vials (10 × 20 ml per package) and must always be diluted before intravenous administration. The concentration of 4 mmol/ml means that each milliliter contains 4 millimoles of ammonium chloride, making it a potent preparation that requires precise dosing calculations by trained medical personnel.
Common causes of metabolic alkalosis
Understanding why metabolic alkalosis develops helps explain when Addex-Ammoniumklorid may be needed. The condition typically arises from one of several clinical situations, and healthcare providers must identify and address the underlying cause alongside correcting the pH imbalance.
- Prolonged vomiting: Loss of gastric acid (hydrochloric acid) through persistent vomiting depletes hydrogen ions and chloride from the body, leading to a rise in blood pH. This is one of the most common causes in the general population.
- Nasogastric suction: In hospitalized patients, continuous suctioning of stomach contents through a nasogastric tube removes acid from the body in a similar manner to vomiting.
- Diuretic therapy: Certain diuretics, particularly loop diuretics (such as furosemide) and thiazide diuretics, can cause metabolic alkalosis by promoting the excretion of chloride and hydrogen ions in the urine.
- Excessive alkali administration: Overuse of antacids or sodium bicarbonate can directly elevate blood pH.
- Hypokalemia: Low potassium levels cause the kidneys to excrete more hydrogen ions, contributing to alkalosis.
Metabolic alkalosis is classified as either chloride-responsive or chloride-resistant. Addex-Ammoniumklorid is particularly effective in chloride-responsive metabolic alkalosis, where the condition is driven by chloride depletion. In these cases, providing both hydrogen ions and chloride ions addresses the root cause of the disturbance. Chloride-resistant forms typically require treatment of the underlying condition, such as mineralocorticoid excess.
What Should You Know Before Using Addex-Ammoniumklorid?
Addex-Ammoniumklorid is contraindicated in patients with severe liver damage. Caution is required in patients with impaired liver or kidney function. Your prescribing physician will assess your medical history and organ function before initiating treatment.
Before administering Addex-Ammoniumklorid, healthcare professionals must conduct a thorough evaluation of the patient's clinical status. This medication, while effective for its intended purpose, requires careful patient selection and monitoring to ensure safe use. The assessment typically includes a review of liver and kidney function, current medications, and the underlying cause of the metabolic alkalosis.
Contraindications
The most important contraindication for Addex-Ammoniumklorid is severe hepatic (liver) impairment. This contraindication exists because the therapeutic mechanism of the drug depends entirely on the liver's ability to convert ammonium ions to urea. In patients with severe liver disease, this metabolic pathway is compromised, leading to the accumulation of ammonia in the blood—a condition known as hyperammonemia. Elevated blood ammonia levels can cause hepatic encephalopathy, a serious neurological condition characterized by confusion, altered consciousness, and in severe cases, coma.
Healthcare providers should also exercise extreme caution when considering Addex-Ammoniumklorid in patients with decompensated cirrhosis, acute hepatitis, or any condition that significantly impairs hepatocyte (liver cell) function. In these patients, alternative approaches to managing metabolic alkalosis should be considered, such as potassium chloride supplementation, acetazolamide, or treatment of the underlying cause.
Warnings and Precautions
Patients should inform their healthcare team about any relevant medical conditions before receiving Addex-Ammoniumklorid. The following conditions require particular caution and close monitoring during treatment:
- Impaired liver function: Even mild to moderate hepatic impairment may affect the metabolism of ammonium chloride. Liver function tests should be reviewed before treatment, and serum ammonia levels should be monitored during infusion.
- Impaired kidney function: The kidneys play a role in acid-base regulation and electrolyte excretion. Patients with renal insufficiency may be more susceptible to the acidifying effects of ammonium chloride, and the drug may accumulate if renal clearance is reduced.
- Respiratory acidosis: In patients who already have a low blood pH due to respiratory causes (such as chronic obstructive pulmonary disease), adding an acidifying agent could worsen the acidemia.
- Electrolyte imbalances: Patients with pre-existing electrolyte disturbances should have these corrected or carefully monitored during ammonium chloride therapy.
Addex-Ammoniumklorid is a concentrated solution that must be diluted before intravenous administration. It should never be injected directly (undiluted) into a vein, as the high concentration can cause severe local irritation, phlebitis, and potentially dangerous rapid shifts in blood pH. Always ensure proper dilution according to hospital protocols before administration.
Pregnancy and Breastfeeding
There are no known risks associated with Addex-Ammoniumklorid at recommended doses during pregnancy or breastfeeding. However, as with all medications administered during pregnancy, it should only be used when the treating physician determines that the clinical benefit justifies any potential risk to the mother and fetus.
Women who are pregnant, breastfeeding, suspect they may be pregnant, or are planning to become pregnant should inform their healthcare provider before receiving this medication. The physician will weigh the necessity of correcting the metabolic alkalosis against any theoretical risks to the pregnancy or nursing infant.
Ammonium chloride crosses the placenta, and while short-term use at therapeutic doses has not been associated with teratogenic effects in clinical practice, prolonged or excessive use should be avoided. In breastfeeding mothers, ammonium chloride may be excreted in small amounts in breast milk, though clinically significant effects on the nursing infant are not expected at recommended doses.
Driving and Operating Machinery
Addex-Ammoniumklorid has no known effects on the ability to drive or operate machinery. However, since the medication is administered intravenously in a hospital setting, this consideration is generally not relevant to patients receiving treatment. Patients should follow their healthcare team's advice regarding activity restrictions related to their underlying medical condition.
How Does Addex-Ammoniumklorid Interact with Other Drugs?
Patients should inform their physician about all medications they are currently taking, have recently taken, or plan to take. While no specific clinically significant drug interactions have been formally documented in the product literature, the acidifying properties of ammonium chloride can theoretically affect the excretion and efficacy of certain pH-sensitive medications.
Drug interactions involving ammonium chloride are primarily related to its effect on urinary pH and systemic acid-base balance. By acidifying the urine and blood, ammonium chloride can alter the ionization state of other drugs, affecting their renal excretion rates, absorption, and distribution. Healthcare professionals managing patients receiving Addex-Ammoniumklorid should consider these potential pharmacokinetic interactions, particularly in patients receiving multiple medications.
The following table summarizes the known and theoretical drug interactions that healthcare providers should be aware of when prescribing ammonium chloride. It is important to note that many of these interactions are based on pharmacological principles rather than extensive clinical trial data, as the drug is typically used in acute clinical settings where careful monitoring is already in place.
| Drug / Class | Type | Mechanism | Clinical Significance |
|---|---|---|---|
| Amphetamines | Pharmacokinetic | Urinary acidification increases renal excretion of amphetamines | May reduce therapeutic effect of amphetamines |
| Salicylates (Aspirin) | Pharmacokinetic | Acidic urine decreases renal elimination of salicylates | Risk of salicylate accumulation and toxicity |
| Methotrexate | Pharmacokinetic | Acidic urine may decrease methotrexate solubility in renal tubules | Increased risk of nephrotoxicity |
| Sodium bicarbonate | Pharmacodynamic | Direct chemical antagonism – bicarbonate neutralizes acidifying effect | Reduced efficacy of ammonium chloride |
| Potassium-sparing diuretics | Pharmacodynamic | Combined acidifying effect may exacerbate metabolic acidosis | Monitor acid-base status closely |
| Aminoglycosides | Pharmacokinetic | Acidic urine may increase renal tubular reabsorption | Monitor drug levels and renal function |
Important Interaction Considerations
In clinical practice, the most relevant interactions to consider are those involving drugs whose excretion is significantly affected by urinary pH. Weakly basic drugs (such as amphetamines, quinidine, and pseudoephedrine) are excreted more rapidly in acidic urine, potentially reducing their therapeutic effects. Conversely, weakly acidic drugs (such as salicylates and barbiturates) are retained longer in acidic urine, potentially increasing their plasma concentrations and risk of toxicity.
Healthcare providers should review the patient's complete medication list before initiating ammonium chloride therapy and consider whether dose adjustments or additional monitoring may be necessary for concomitant medications. Regular monitoring of blood pH, electrolytes, and relevant drug levels is advisable throughout treatment.
What Is the Correct Dosage of Addex-Ammoniumklorid?
Addex-Ammoniumklorid is given as an intravenous infusion after dilution. The dosage is individualized based on the patient's acid-base status, body weight, and clinical condition. Your physician will determine the appropriate dose and infusion rate guided by regular blood gas analysis and electrolyte monitoring.
The dosing of Addex-Ammoniumklorid is highly individualized and depends on the severity of the metabolic alkalosis, the patient's weight, renal function, and ongoing acid-base losses. Unlike many medications with fixed dosing schedules, ammonium chloride therapy requires continuous assessment and adjustment based on laboratory values, particularly arterial blood gas (ABG) analysis and serum electrolyte panels.
The general approach to dosing involves calculating the chloride deficit and the base excess to estimate the amount of ammonium chloride needed to correct the alkalosis. However, it is critical to correct the pH gradually rather than rapidly, as sudden changes in acid-base status can be dangerous. Typically, no more than 50% of the calculated deficit is corrected in the first 12–24 hours, with the remainder corrected over subsequent days.
Adults
Standard Adult Dosing
The dose is calculated based on the degree of metabolic alkalosis as determined by blood gas analysis. A commonly used formula estimates the ammonium chloride requirement as:
Dose (mmol) = 0.2 × body weight (kg) × base excess (mmol/L)
Half of this calculated dose is typically administered over the first 12–24 hours, with the infusion rate generally not exceeding 20 mmol/hour (5 ml/hour of the 4 mmol/ml concentrate). The solution must be diluted in a compatible intravenous fluid (such as 0.9% sodium chloride or 5% dextrose) before administration.
Children
Pediatric Dosing
Pediatric dosing follows the same principles as adult dosing but requires even more careful calculation based on the child's weight and acid-base status. Children are more sensitive to shifts in acid-base balance, and doses should be calculated conservatively. Treatment should be administered under the supervision of a pediatric intensivist or pediatrician experienced in managing acid-base disorders. Frequent blood gas monitoring is essential.
Elderly
Geriatric Dosing
Elderly patients may have age-related declines in liver and kidney function that affect the metabolism and excretion of ammonium chloride. Dosing should be conservative, and more frequent monitoring of liver function, renal function, ammonia levels, and acid-base status is recommended. Lower infusion rates may be appropriate in patients with reduced hepatic or renal reserve.
Missed Dose
Since Addex-Ammoniumklorid is administered as a continuous or intermittent intravenous infusion in a hospital setting, the concept of a missed dose is generally not applicable. The infusion rate and duration are managed by the healthcare team, who adjust the treatment based on ongoing laboratory results. If an infusion is interrupted, the physician will reassess the patient's acid-base status and determine whether to resume treatment and at what rate.
Overdose
Administration of excessive amounts of ammonium chloride can lead to several serious complications that require immediate medical attention:
- Metabolic acidosis: Overcorrection of alkalosis can push the blood pH below the normal range (below 7.35), causing symptoms such as rapid breathing (Kussmaul respirations), confusion, fatigue, and in severe cases, cardiovascular collapse.
- Hyperammonemia: If the liver's capacity to convert ammonium to urea is overwhelmed, toxic levels of ammonia can accumulate in the blood. Symptoms include tremor, slurred speech, altered consciousness, and potentially coma.
- Hyperchloremia: Excessive chloride administration can lead to a hyperchloremic metabolic acidosis, compounding the acid-base disturbance.
- Local vein irritation: Rapid or concentrated infusion can cause pain, phlebitis, and thrombosis at the injection site.
Treatment of ammonium chloride overdose involves immediate discontinuation of the infusion, supportive care, and correction of the resulting acid-base imbalance. Sodium bicarbonate may be administered to correct severe metabolic acidosis. Serum ammonia, electrolytes, and blood gases should be monitored continuously. In cases of severe hyperammonemia, hemodialysis may be necessary.
What Are the Side Effects of Addex-Ammoniumklorid?
No side effects have been reported when Addex-Ammoniumklorid is used according to recommended dosing guidelines. However, excessive or improper administration can potentially cause metabolic acidosis, hyperammonemia, or local infusion site reactions.
The safety profile of Addex-Ammoniumklorid is favorable when the medication is administered according to established dosing protocols. The product information states that no adverse effects have been reported at recommended doses, which reflects both the medication's inherent safety when properly used and the careful monitoring that accompanies its administration in hospital settings.
However, it is important for both healthcare providers and patients to understand the potential adverse effects that could occur, particularly in the context of overdose, excessively rapid infusion, or use in patients with compromised liver or kidney function. The following frequency grid categorizes potential adverse effects based on pharmacological principles and clinical experience with ammonium chloride preparations.
No Reported Side Effects at Recommended Doses
When used as directed
- No adverse effects have been documented in the product literature when recommended dosing guidelines are followed
- The medication has a well-established safety profile in clinical use
Potential Effects with Rapid Infusion
May occur if infusion rate is too fast
- Nausea and vomiting
- Pain or irritation at the infusion site
- Headache
- Hyperventilation (compensatory response to acidification)
Potential Effects with Excessive Dosing
May occur with overdose or in susceptible patients
- Metabolic acidosis (overcorrection of alkalosis)
- Hyperchloremia (elevated blood chloride levels)
- Hypokalemia (low potassium levels)
- Calcium loss through increased urinary excretion
Serious Effects (Overdose or Contraindicated Use)
Rare; primarily in patients with liver impairment
- Hyperammonemia (elevated blood ammonia levels)
- Hepatic encephalopathy (confusion, altered consciousness)
- Cardiac arrhythmias (due to electrolyte disturbances)
- Phlebitis or thrombosis at infusion site (if inadequately diluted)
Reporting Suspected Side Effects
Reporting suspected adverse reactions after a medicine has been authorized is important, as it allows continuous monitoring of the medicine's benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected side effects to their national pharmacovigilance authority. In the European Union, reports can be submitted through the national reporting systems of each member state. In the United States, adverse events can be reported to the FDA through the MedWatch program.
Early reporting of unexpected side effects contributes to the overall safety surveillance of medications and can help identify rare adverse reactions that may not have been detected during clinical trials. Even if you are unsure whether a symptom is related to the medication, it is better to report it and let the pharmacovigilance authorities assess the potential connection.
How Should You Store Addex-Ammoniumklorid?
Store Addex-Ammoniumklorid out of the sight and reach of children. Do not use after the expiry date on the label. No special storage conditions are required. Once opened, use immediately.
Proper storage of medications is essential to maintain their efficacy and safety. Addex-Ammoniumklorid, like all pharmaceutical preparations, must be stored according to specific guidelines to ensure that the product remains stable and effective throughout its shelf life.
The following storage guidelines should be observed for Addex-Ammoniumklorid:
- Keep out of sight and reach of children: As with all medications, Addex-Ammoniumklorid should be stored in a secure location that is inaccessible to children. In hospital settings, this means storing the medication in designated pharmaceutical storage areas with controlled access.
- Check the expiry date: Do not use Addex-Ammoniumklorid after the expiry date printed on the label after “EXP.” The expiry date refers to the last day of the stated month. Using expired medications can lead to reduced efficacy and potentially altered chemical composition.
- No special storage conditions: The product does not require refrigeration or protection from specific temperature ranges under normal storage conditions. However, it should be stored at room temperature and protected from extreme heat or freezing.
- Inspect before use: Before administration, the solution should be visually inspected for any particulate matter, discoloration, or signs of contamination. The solution should be clear and free of visible particles. Do not use the product if the solution appears cloudy, discolored, or contains precipitates.
- Single-use preparation: Once the vial is opened, the solution should be used immediately. Any unused portion should be discarded according to local pharmaceutical waste disposal guidelines. Do not store opened vials for later use.
Do not dispose of medications via household waste or wastewater. In hospital settings, unused ammonium chloride solution should be disposed of according to the institution's pharmaceutical waste management protocols. Patients who have questions about medication disposal should consult their pharmacist or healthcare provider for guidance on proper disposal methods in their jurisdiction.
What Does Addex-Ammoniumklorid Contain?
Addex-Ammoniumklorid contains ammonium chloride (4 mmol/ml) as the active substance. The only excipient is water for injections. The product is supplied in glass injection vials in a package size of 10 × 20 ml.
Understanding the composition of a medication is important for healthcare professionals and patients alike, particularly for identifying potential allergens or incompatible substances. Addex-Ammoniumklorid has a simple formulation, which reduces the risk of excipient-related adverse reactions.
Active Ingredient
The active substance is ammonium chloride at a concentration of 4 mmol/ml. Ammonium chloride (chemical formula: NH4Cl) is a white crystalline salt that is highly soluble in water. It has a molecular weight of 53.49 g/mol. In solution, it dissociates into ammonium ions (NH4+) and chloride ions (Cl−), both of which contribute to the therapeutic effect of the medication.
Excipients
The only excipient in Addex-Ammoniumklorid is water for injections (aqua ad iniectabilia). Water for injections is a highly purified form of water that meets strict pharmacopeial standards for sterility, pyrogen content, and chemical purity. The use of a single, simple excipient means that the risk of allergic or hypersensitivity reactions to inactive ingredients is minimal.
Appearance and Packaging
Addex-Ammoniumklorid is a clear, colorless aqueous solution. It is supplied in glass injection vials, which provide excellent chemical compatibility and protect the solution from degradation. The standard package contains 10 vials of 20 ml each, providing a total volume of 200 ml per package (equivalent to 800 mmol of ammonium chloride per package).
The glass vials are pharmaceutical grade and are designed for single use. Each vial is sealed with a rubber closure and an aluminum crimp cap to maintain sterility until the point of use. The label on each vial includes the product name, strength, batch number, expiry date, and storage instructions.
Manufacturer Information
Addex-Ammoniumklorid is manufactured by Fresenius Kabi, one of the world's leading providers of intravenous therapies, clinical nutrition products, and medical devices for critically and chronically ill patients. Fresenius Kabi operates globally and adheres to Good Manufacturing Practice (GMP) standards as required by the European Medicines Agency (EMA) and other regulatory authorities worldwide.
Frequently Asked Questions about Addex-Ammoniumklorid
Medical References
All information is based on international medical guidelines and peer-reviewed research.
- World Health Organization (WHO) (2023). "Model List of Essential Medicines – 23rd List." WHO Essential Medicines WHO's comprehensive list of essential medicines for healthcare systems worldwide.
- European Medicines Agency (EMA). "Guideline on Summary of Product Characteristics (SmPC)." EMA Guidelines European regulatory standards for pharmaceutical product information.
- British National Formulary (BNF). "Ammonium Chloride – Electrolyte Imbalances." BNF Online UK prescribing guidance for ammonium chloride in electrolyte management.
- Galla JH (2000). "Metabolic Alkalosis." Journal of the American Society of Nephrology. 11(2):369–375. Comprehensive review of the pathophysiology and management of metabolic alkalosis.
- Khanna A, Kurtzman NA (2001). "Metabolic Alkalosis." Respiratory Care. 46(4):354–365. Clinical review of acid-base disorders including the role of ammonium chloride in treatment.
- Sweetman SC, ed. (2014). "Martindale: The Complete Drug Reference." 38th ed. Pharmaceutical Press. Comprehensive pharmaceutical reference including ammonium chloride monograph.
- Fresenius Kabi. "Addex-Ammoniumklorid – Summary of Product Characteristics." Official product information from the marketing authorization holder.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in pharmacology, internal medicine, and critical care medicine.